Clinical trial
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
NCT01248247
Study timeline
Study start (actual)2011-06-02Date precision: day
Registry last updated2022-01-12
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Lung Cancerunresolved
Interventions
ErlotinibDRUG · verified · RxNorm: erlotinib
AZD6244DRUG
MK-2206DRUG
SorafenibDRUG · verified · RxNorm: sorafenib
ErlotinibDRUG · verified · RxNorm: erlotinib
MK-2206DRUG
Sponsors & collaborators
M.D. Anderson Cancer Centerlead sponsor
Merck Sharp & Dohme LLCcollaborator
National Cancer Institute (NCI)collaborator
GlaxoSmithKlinecollaborator
Novartiscollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01248247 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.